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Background: As part of an investigation into the respiratory health in children conducted in Torino, northwestern
Italy, our aim was to assess development in lung function from childhood to adolescence, and to assess changes or
persistence of asthma symptoms on the change of lung function parameters. Furthermore, the observed lung
function data were compared with the Global Lung Function Initiative (GLI) reference values.
Methods: We conducted a longitudinal study, which lasted 7 years, composed by first survey of 4–5 year-old children
in 2003 and a follow-up in 2010. Both surveys consisted in collecting information on health by standardized SIDRIA
questionnaire and spirometry testing with FVC, FEV1, FEV1/FVC% and FEF25–75 measurements.
Results: 242 subjects successfully completed both surveys. In terms of asthma symptoms (AS = asthma attacks or
wheezing in the previous 12 months), 191/242 were asymptomatic, 13 reported AS only in the first survey (early
transient), 23 had AS only in the second survey (late onset), and 15 had AS in both surveys (persistent). Comparing the
lung function parameters observed with the predicted by GLI only small differences were detected, except for FVC and
FEF25–75, for which more than 5% of subjects had Z-score values beyond the Z-score normal limits. Furthermore, as well
as did not significantly affect developmental changes in FVC and FEV1, the decrease in FEV1/FVC ratio was significantly
higher in subjects with AS at the time of follow-up (late onset and persistent phenotypes) while the increase in
FEF25–75 was significantly smaller in subjects with persistent AS (p < 0.05).
Conclusions: The GLI equations are valid in evaluating lung function during development, at least in terms of lung
volume measurements. Findings also suggest that the FEF25–75 may be a useful tool for clinical and epidemiological
studies of childhood asthma.
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The prevalence of childhood pulmonary diseases, es-
pecially bronchial asthma, is increasing worldwide
[Global Initiative for Asthma (GINA) 2012, http://www.
ginasthma.org/]: lung disorders in children [1,2] are most
frequently of obstructive type and usually limited to the
intrathoracic-intrapulmonary airways [3].
Reliable information of lung function would greatly
benefit clinical assessment and patient follow-up. Studies
on respiratory function tests in children and adolescents
have been published [4], and specific criteria have been
proposed for acceptable maximal expiratory flow volume
(MEFV) and other reference values [5,6]. Findings* Correspondence: roberto.bono@unito.it
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unless otherwise stated.arising from many of these studies have been assembled
to generate the reference lung function equations pro-
posed by the Global Lung Function Initiative (GLI) [7-9]
of the European Respiratory Society. The Global Lung
Project in 2012 (http://www.lungfunction.org/tools/90-
equations-and-toolsml. The) published multi-ethnic ref-
erence equations for spirometry that span all-ages. How-
ever, these equations are until today not enough tested
on the field, especially in children.
While lung development is a continuous process dur-
ing childhood, lung function is dependent on age, gen-
der, height, and ethnicity [10]. Both lung volume and
forced expiratory volumes increase during this period,
but not at the same rate [11]. Forced vital capacity
(FVC) is affected by changes in muscular strength, by
the shape and stiffness of the thorax, and by the numberl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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example by the FEV1, is also affected by the caliber of
the airways, and by lung and airways elasticity. In child-
hood, the FVC increases more rapidly than the FEV1,
leading to falls in the FEV1/FVC ratio, but these trends
are temporarily reversed in adolescence [11] before con-
tinuing to decrease during adult life. Measurement of
lung function is important for the evaluation of physical
development and the presence of disease but few studies
evaluated the effects of respiratory symptoms and their
possible changes over time on transformation of lung
function parameters.
In 2003, we studied a group of children, age 3–6 years,
attending kindergarten in Torino, Italy [5]. We collected
data on respiratory function (by spirometry) and respira-
tory health (by standardized questionnaire) [12]. In 2010,
we carried out a follow-up study of the same group of
children.
The aims of the present study were: 1) to establish if our
data, drawn from a Northern Italian population, conforms
with the GLI reference values; 2) to assess changes in lung
function and to evaluate the effects of asthma symptoms
(AS) on changes of lung function parameters in children
during the transition to adolescence.
Methods
Study population
As part of a research project funded by the Piedmont
Regional Council (northwest Italy) focusing on the ef-
fects of environmental pollution in preschoolers, in 2003
we studied 960 children, aged 3–6 years, drawn from 18
kindergarten schools located in Torino (6.700 inhabi-
tants/km2, 240 m a.s.l.), an urbanized Italian city with al-
most 900.000 inhabitants. This initial cohort was
whittled down to 766 children as some declined to par-
ticipate or spirometry testing was deemed invalid. To
update the database in 2010, we again contacted the in-
dividuals studied in 2003. The demographic information
provided by the parents, together with the information
within the 2003 consent forms, allowed us to recon-
struct a database of 573 children, now drawn from 20
secondary schools located in Torino. Each child was
given the same the identification code in the 2003 and
2010 surveys to facilitate data comparison between sur-
veys. Since the subjects were underage, during a public
meeting in both the two occasions, parents and teachers
were informed on the objective of this study. A written
informed consent was signed and delivered by each the
participants’ parents. Thus, the participation of all the
subjects did not occur until after informed consent was
obtained. However, the local Ethics Committee “San
Luigi Gonzaga Hospital” (previously named “ASL TO2”)
has expressed a favorable opinion with practice number
826/13/08.Questionnaire
Child health information was collected in the 2003 and
2010 surveys using the same standardized SIDRIA (Italian
Studies on Respiratory Disorders in Children and the En-
vironment) questionnaire [12,13] compiled by the parents.
The questionnaire was administered aiming to check the
presence of respiratory symptoms and related risk factors.Spirometry
Written informed consent was obtained from the par-
ents prior to both 2003 and 2010 measurements. Spir-
ometry was carried out in the morning during school
activities. Height (measured with a stadiometer), weight
and body mass index (BMI) (computed as weight/
height2) of each child were also recorded. Pulmonary
function was measured using a turbine-based Master-
scope Rotary Jaeger spirometer with subjects standing
and wearing a nose-clip. In 2003, we organized the chil-
dren into small groups and, with playful communication,
we explained how to carry out the test. All the tests were
performed using special incentive spirometry software
(“blowing out candles” software). Spirometry testing was
performed in a similar manner in 2010, without the use
of “blowing out candles” software. In both surveys, each
child recorded 3–6 MEFV curves within a 10–15 min
interval. Subjects with only one acceptable measurement
were excluded from the analysis. The exclusion criteria
adopted in 2003 are specified elsewhere. In particular we
have considered not acceptable the manoeuvres with: a)
a sub-maximal expiratory effort in which a peak expira-
tory flow (PEF) was not clearly determined (i.e. in pres-
ence of flat or rounded curves), or with slow rise of PEF
(top of the curve to the right) [14,15]; b) evidence of
cough or glottis closure [6]; c) an expiration time lesser
than 0.5 seconds [15]; d) an abrupt end of expiration ef-
fort (presence of a sharp drop or cessation in flow from
a point in which the flows where >25% of PEF) [14,15].
Furthermore, children with reported skeletal anomalies
or lung diseases, other than asthma, were excluded [5].
In 2010, the exclusion criteria adopted were in accord-
ance with the current guidelines [10]. For subjects who
reported actual acute symptoms or taking drugs for re-
spiratory disorders, the examination was rescheduled
after adequate washout period (at least 24 hours) or
symptom remission.Statistical methods
Lung function test results were used only if valid in both
surveys. Descriptive statistics on both occasions were
performed and reported for all subjects. All analysis
were performed by means of STATA® 12 statistical pack-
age (StataCorp College Station, Texas 77845 USA). In
the analyses, asthma symptoms (AS) where defined as
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wheezing in the previous 12 months.
The subjects were categorized as following: asymptom-
atic if AS was absent in both surveys, early transient
with AS in the first but not in the second survey, late
onset with AS in the second survey only and persistent if
AS was presents in both surveys. Following the results
of Box-Cox regression, Linear transformations were ap-
plied when indicated to correct for heteroscedasticity
and deviation from normal distribution.
To assess how our data for FEV1, FVC, FEV1/FVC%
and FEF25–75 conformed with the GLI reference values,
the GLI reference values were computed for each subject
by means of the GLI-2012 Desktop Software for Data
Sets vs 1.3.4, available on the web site http://www.lung-
function.org/tools/90-equations-and-tools/196-obtain-
software.html.
The means of observed values in asymptomatic as
measured in each survey and values predicted by GLI
were compared by means of t-test for paired data. The
Z-score were also computed and the 5th and 50th per-
centiles were reported.
To measure the effects of time, anthropometric vari-
ables and symptoms on changes in lung function param-
eters over the time, annual changes were computed as
the difference between the parameters from the second
and the first survey, divided by years of follow-up. An-
nual changes were used in a set of multiple regressionsTable 1 Characteristics and findings of lung function test of t
survey
FEMALE MALE
2003 2010 Δ/year 2003
Mean Mean Mean Mean
(sd) (sd) (sd) (sd)
AGE 4.5 11.7 7.34 4.5
(0.7) (0.6) (0.48) (0.6)
HEIGHT (cm) 110.3 150.1 5.3 111.7
(6.2) (8.5) (0.7) (6.3)
WEIGHT (Kg) 18.8 42.6 3.4 20.0
(3.2) (9.3) (1.2) (3.8)
BMI% 15.4 18.6 0.41 15.9
(1.8) (3.7) (0.59) (2.0)
FVC(ml) 1054 2647 221 1144
(239) (508) (55) (226)
FEV1(ml) 1048 2293 176 1127
(224) (420) (44) (211)
FEV1%/FVC 96.6 85.3 −1.7 96.3
(4.4) (7.4) (1.1) (4.1)
FEF25–75(ml/s) 1561 2718 159 1735
(385) (728) (88) (949)as dependent variable, and gender and time varying co-
variates (anthropometric values: height, weight, BMI)
and AS in both occasions as predictors, using asymp-
tomatic subjects group as reference. Marginal means
with confidence intervals (C.I.) at 95% were calculated
from predictions at mean values of covariates and aver-
aging over symptoms at the follow-up.Results
In 2010, we traced and contacted 573 of the 766 chil-
dren studied in 2003; of these, 174 declined to partici-
pate in the second survey. Consequently, the follow-up
survey had 399 participants, mean age 11.8 years, drawn
from 20 primary and secondary schools in Torino. Of
these 399 subjects, 242 (60.3% males) adequately per-
formed lung function tests in both surveys, and only
these subjects were included in this analysis. The deci-
sion to participate in the surveys was not influenced by
anthropometric variables or symptoms. Table 1 reports
the main anthropometric characteristics and results of
lung function tests in the two surveys.
Among the 242 subjects, 28 (11.6%) had AS in the first
survey, 38 (17%) had AS in the second survey whereas
191 subjects did not have AS in either survey. Other-
wise, from a longitudinal point of view, 13 children re-
ported AS in the first but not in the second survey (early
transient), 23 reported AS only in the second surveyhe 242 subjects at the first (2003) and second (2010)
TOTAL
2010 Δ/year 2003 2010 Δ/year
Mean Mean Mean Mean Mean
(sd) (sd) (sd) (sd) (sd)
11.8 7.23 4.5 11.8 7.30
(0.7) (0.43) (0.7) (0.7) (0.46)
150.7 5.5 111.1 150.4 5.5
(8.8) (0.7) (6.3) (8.7) (0.7)
44.8 3.3 19.5 43.9 3.3
(11.3) (1.0) (3.6) (10.5) (1.0)
19.0 0.44 15.7 18.8 0.43
(4.9) (0.46) (1.9) (4.4) (0.54)
2842 231 1105 2756 227
(533) (55) (236) (530) (55)
2426 177 1093 2367 177
(460) (52) (220) (447) (48)
83.7 −1.8 96.4 84.3 −1.8
(6.0) (0.9) (4.3) (6.5) (1.0)
2706 131 1660 2711 143
(731) (162) (761) (729) (136)
Table 2 Distribution of asthma symptoms (AS = Asthma
or wheezing in the previous 12 months) on two
observations
No symptoms Early transient Late onset Persistent
N 191 13 23 15
% 78.93 5.37 9.5 6.2
Table 3 Means and changes by year of lung function parame
for asymptomatic subjects, compared with t-test for paired d
2003
Mean
FEV1 (ml) Observed 1107.4
Predicted 1123.2
δ −15.8
95% CI of δ (−32.8 - +5.6)
Z-score 50tile −0.138
Z-score 5tile −1.583
lln 879.5
FVC (ml) Observed 1120.7
Predicted 1216.0
δ −95.2
95% CI of δ (−116.2 - -74.3)
Z-score 50tile −0.645
Z-score 5tile −1.954
lln 943.9
FEV1/FVC (%) Observed 96.6
Predicted 92.9
δ 3.7
95% CI of δ (+3.0 - +4.3)
Z-score 50tile 0.961
Z-score 5tile −0.905
lln 81.6
FEF25–75 (ml/s) Observed 1621.3
Predicted 1602.6
δ 18.7
95% CI of δ (−25.0 - +62.3)
Z-score 50tile 0.045
Z-score 5tile −1.357
lln 967.0
Legend:
δ: Observed. Predicted by GLI.
Δ: (Differences between the 2 occasions/Years of follow-up).
* p < 0.05 ** p < 0.01.
CI = Confidence interval.
Z-Score = (standard deviation scores from regression Equation).
50tile = Median 5tile = fifth percentile.
lln = lower limit of normality of predicted values.
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(persistent) (Table 2).
The Table 3 shows the results of comparison of ob-
served with the GLI predicted values for FEV1, FVC,
FEV1/FVC % and FEF25–75 in asymptomatic subjects.
The FEV1, FVC observed values were lower than pre-
dicted in both surveys while FEV1/FVC% and FEF25–75
were lower than predicted in the second occasion only;
the differences were significant at 5% level. However, theter observed and predicted from GLI and their differences
ata
2010 Δ/year
p Mean p p
2435.9 180.4
2497.5 188.3
NS −61.6 * −7.9 *
(−103.4 –19.8)
−0.203
−1.548
2017.8
2824.1 233.4
2876.4 227.8
** −52.3 ** 5.6 **
(−91.9 - -12.7)
−0.113
−1.468
2329.9
85.5 −1.57
87.1 −0.8
** −2.4 ** −0.77 **
(−2.4 - -0.8)
−0.207
−1.664
76.3
2766.9 152.8
2955.8 185.2
NS −269.6 ** −32.3 **
(−269.6 - -108.2)
−0.306
−1.912
1954.3
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were within the range of normal variation of the refer-
ence values except for of the values of FVC in both oc-
casions and FEF25–75 in the second one, where more
than five percent (but less than 10%) of the subjects fell
below the lower predicted Z-score.Table 4 Lung Function parameters in the first survey and ann
gender with multiple regression analysis
2003
Mean
(C.I.)
FEV1 (ml) No symptoms 1108.8
(1087.6-
Early transient 1122.3
(1032.2-
Late onset 1105.7
(1045.31
Persistent 1100.2
(1030.5
FVC (ml) No symptoms 1121.4
(1100.6
Early transient 1159.3
(1072.7-
Late onset 1134.6
(1072.3
Persistent 1151.5
(1074.3
FEV1/FVC (%) No symptoms 96.5
(95.9 - 9
Early transient 94.2
(91.5 - 9
Late onset 96.7
(94.9 - 9
Persistent 95.9
(93.8 - 9
FEF25–75 (ml/s) No symptoms 1621.9
(1580.6
Early transient 1531.5
(1353.4
Late onset 1570.3
(1447.4
Persistent 1506.4
(1354.2
- * P < 0.05.
- ** P < 0.01.
Δ: (Differences between the 2 occasions/Years of follow-up)
Note: the statistical significativity in the last column is for the model; the * in the ce
asymptomatic subjects mean.The marginal means (and C.I. 95%) of the lung func-
tion parameters (adjusted for height and gender) mea-
sured in the first survey and their annual changes are
shown (Table 4), stratified according to AS status. The
Figure 1 shows the adjusted means of annual changes by
symptom group: the lung function levels measuredual changes (mean and C.I. 95%) adjusted for height and
Δ/year P<
Mean model
(C.I.)
181.9 NS
1129.9) (176.0 -187.9)
186.9
1212.4) (161.8 - 212.1)
171.5
-166.0) (154.6 - 188.4)
172.0
- 1169.9) (152.4 - 191.5)
233.8 (228.4 - 239.3) NS
- 1142.1)
232.2
1245.8) (208.4 - 255.9)
229.0
- 1197.0) (212.5 - 245.4)
234.9
- 1228.7) (214.5 - 255.4)
−1.5 *
7.2) (−1.7 - -1.4)
−1.1
7.0) (−1.7 - -0.6)
−1.8
8.5) (−2.2 - -1.4)
−2.0 *
8.0) (−2.4 - -1.6)
157.4 ***
- 1663.1) (146.8 - 168.0)
158.6
- 1709.6) (113.0 - 204.1)
135.5 *
- 1693.1) (104.0 - 166.9)
113.7 **
- 1658.6) (74.7 - 152.7)
ll reports the significativity of the difference of the mean compared with the
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not significantly different among symptoms status groups.
However, annual changes seemed to be affected by AS.
When volumes were taken into account, AS of symptom-
atic subjects did not induced significant changes in FVC,
FEV1 if compared to asymptomatic subjects. Comparing
the symptomatic subjects to asymptomatic ones, the de-
crease in the FEV1/FVC% was significantly higher in sub-
jects with AS in the second survey (late onset and
persistent), but not in transient. Finally, FEF25–75 showed
a significantly higher decrease in subjects with persistent
AS (p < 0.05).
Discussion
The interpretation of functional parameters in the tran-
sition from childhood to adolescence was highlighted by
the multiplicity of reference values and the discontinuity
between age groups. The Global Lung Initiative (GLI)
equations are the first global multiethnic reference equa-
tions for spirometry that span all ages and which seem
to have solved this problem. A major limitation of any
reference equation is that it is based on a cross-sectional
snapshot of a population composed of individuals at dif-
ferent ages, but the age differences do not necessarily re-
flect the individual changes over time [16-18]. However,
our results suggest that, at least for the age and time range
examined in this study, the predictions of the GLI refer-
ence equations are a good approximation of the changes150
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Figure 1 Annual mean changes of lung function parameters (adjusted
groups. Note: The * indicates the groups with significant difference at 5% levin lung function observed over time and adequately de-
scribe pulmonary function in growing subjects.
When we compared the values observed in asymptom-
atic subjects with the predicted by the GLI, the means
were consistently different only for FVC and FEF25–75.
Although, for the most part of subjects these differences
were within the range of normal variation of the GLI ref-
erences values, they may indicate that some regional dif-
ferences are possible, even among the same ethnic
group. Thus, at least for FEF25–75, we recommend the
use of regional data; at least until a proper longitudinal
equation including individuals who have completed their
lung growth.
Factors having a negative impact on the age-related
growth of pulmonary function in children and adolescents
may result in a lower maximally attained level of pulmon-
ary function and perhaps in an earlier onset in decline of
pulmonary function. Therefore, these factors potentially in-
crease the risk of subsequently developing both reversible
and irreversible obstructive pulmonary diseases [17-19].
Numerous follow-up studies in children with asthma
have consistently shown that more severe respiratory
symptoms in childhood predict reduced lung function in
early adulthood [20,21]. In the mean time, epidemio-
logical studies of childhood asthma are highlighting the
causality between asthma and deficits in lung function, al-
though the characteristics of growth in pulmonary func-
tion from childhood to adulthood are not completely200
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function and asthma are, respectively, the cause or the ef-
fect of one another is crucial for the prevention of asthma
and for our understanding of the origins of this important
disease. The contradictory results can be due to differ-
ences in the frequency of assessment, cohort retention
rates, and the use of quantitative measurements [27,28].
In the present study, the longitudinal analysis of a co-
hort of children examined in 2003 and 2010 showed that
the presence of wheezing disorders (wheezing or asthma
attack) at the time of both measurements (persistent
phenotype) was associated with a smaller increase in
forced flows (particularly FEF25–75). In contrast, changes
in the FEV1/FVC% (and FEV1 and FEV0.5, although not
statistically significant at 5% level) was affected by the
presence of symptoms in the second measurement.
The FEV1 (and the FEV1/FVC%), which is considered
to be reproducible and to represent an appropriate
measure of airway obstruction, often shows normal
values even in children with symptoms of uncontrolled
asthma. In this regard, asthmatic patients may have ven-
tilatory defects in the presence of normal FEV1 [29-32].
The FEF25–75 is a more sensitive marker of symptomatic
asthma than the FEV1 in children [31] and in adults [32].
The middle volume flow rates, measured by the FEF25–75,
is theoretically less effort-dependent than the FEV1, also
because FEF25–75 is a measurement of the “small airways”
patency [32,33] and does not include high flows in the
lung volume. On the contrary, the guidelines of the
American Thoracic Society and the GLI do not suggest
that the assessment of FEF25–75 could play a significant
role in the measurement of airflow obstruction [10,34].
The coefficient of variation of instantaneous flow is quite
large, which partly explains their unsatisfactory perform-
ance in clinical decision-making. Moreover, the broncho-
dilators can affect the natural transformations of flows
and, consequently, the values of FVC, making them no
longer comparable with one another.
On the other hand, the FEF25–75 measured in children
provides, compared to the FEV1, additional information
about clinical status and airway inflammation. Further-
more, the FEF25–75 is well correlated with bronchodilator
responsiveness in asthmatic children with normal FEV1,
and the FEF25–75 is associated with increased childhood
asthma severity and morbidity [35].
Middle volumes flows rates, particularly the FEF25–75,
seem to be a more sensitive indicator of small airway
disease. Despite concerns of test-to-test variability and
the lack of a clearly defined normal range, our findings
suggest that the FEF25–75 is clinically relevant in children
with asthma and could distinguish between subjects with
symptoms that persist over time from subjects with tran-
sient or late-onset symptoms. However, in large and sta-
tistically powerful studies, that can compensate for thevariability, the FEF25–75 can be a useful tool to detect
mean differences between groups with different clinical
characteristics. In these circumstances, the benefits of
the increased physiological sensitivity of the FEF25–75
remain.
Study potential limitations
A possible limitation of this study could either be the rele-
vant loss of subjects to follow-up because we were not
able to trace them or because the subjects declined to re-
peat lung function testing or were not able to perform it.
A further limitation can be due to impossibility to meas-
ure FEV1 in some children 3–4 years [5] aged because
their expiratory time was less than 1 second: this pro-
duced a loss of subjects for longitudinal comparison.
Due to the initial estimate, the sample size in the
symptomatic strata could be too small to show as statis-
tically significant effects. However, although still inaccur-
ate the estimation and the relative confidence intervals
are quite informative to assess the direction of the
effects.
Conclusions
Our results confirm the validity of the GLI reference
equations in evaluating lung function during growth, at
least as regards the dynamic volumes. Furthermore, our
results highlight the usefulness of FEF25–75 measurement
as a tool for clinical and epidemiological studies of
asthma in children.
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